Business Description

Connect Biopharma Holdings Ltd
Description
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 221.62 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -68.5 | |||||
3-Year EPS without NRI Growth Rate | -69 | |||||
3-Year FCF Growth Rate | -99.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 37.09 | |||||
9-Day RSI | 36.63 | |||||
14-Day RSI | 36.03 | |||||
6-1 Month Momentum % | -32.29 | |||||
12-1 Month Momentum % | -35.7 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.25 | |||||
Quick Ratio | 9.25 | |||||
Cash Ratio | 8.81 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.5 | |||||
Shareholder Yield % | -0.34 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -51.75 | |||||
ROA % | -46.73 | |||||
ROIC % | -418.08 | |||||
ROC (Joel Greenblatt) % | -1228.7 | |||||
ROCE % | -51.34 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.28 | |||||
Price-to-Tangible-Book | 0.28 | |||||
EV-to-EBIT | 0.83 | |||||
EV-to-EBITDA | 0.84 | |||||
EV-to-FCF | 1.14 | |||||
Price-to-Net-Current-Asset-Value | 0.29 | |||||
Price-to-Net-Cash | 0.31 | |||||
Earnings Yield (Greenblatt) % | 120.48 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CNTB
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Connect Biopharma Holdings Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -1.578 | ||
Beta | 0 | ||
Volatility % | 69.81 | ||
14-Day RSI | 36.03 | ||
14-Day ATR ($) | 0.064154 | ||
20-Day SMA ($) | 0.78322 | ||
12-1 Month Momentum % | -35.7 | ||
52-Week Range ($) | 0.5347 - 1.58 | ||
Shares Outstanding (Mil) | 55.07 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Connect Biopharma Holdings Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Connect Biopharma Holdings Ltd Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Connect Biopharma Holdings Ltd Frequently Asked Questions
What is Connect Biopharma Holdings Ltd(CNTB)'s stock price today?
The current price of CNTB is $0.65. The 52 week high of CNTB is $1.58 and 52 week low is $0.53.
When is next earnings date of Connect Biopharma Holdings Ltd(CNTB)?
The next earnings date of Connect Biopharma Holdings Ltd(CNTB) is 2024-09-12 Est..
Does Connect Biopharma Holdings Ltd(CNTB) pay dividends? If so, how much?
Connect Biopharma Holdings Ltd(CNTB) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |